Video |

Access challenges for HIV opportunistic infection drug L-AmB

In this short "3 Questions" video, Helen Bygrave, Chronic Diseases Advisor, MSF Access Campaign, talks about the challenges faced by patients and providers in accessing liposomal amphotericin B (L-AmB), a key drug used to treat cryptococcal meningitis, an HIV opportunistic infection that is the number two killer of people living with HIV/AIDS, after TB.